Search clinical trials for: CVL-865

Total 1435 results

Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

Panic Disorder

United States
Cerevel Therapeutics, LLC

Recruiting

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Seizures

United States, Poland, Spain, Serbia, Australia, Ukraine
Cerevel Therapeutics, LLC

Completed

A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects

Panic Disorder

Netherlands
Cerevel Therapeutics, LLC

Enrolling by invitation

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Seizures

United States, Spain, Australia, Poland, Ukraine
Western University of Health Sciences

Completed

Entrainment Between Clinician and Patient During Palpation

Doctor Patient Relation

United States
Atara Biotherapeutics

No longer available

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Epstein-Barr Virus (EBV) Infections | EBV+ Associated Lymphoma | EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Epstein-Barr Viremia | Lymphoma, AIDS-related | Epstein-Barr Virus-associated Lymphoproliferative... and other conditions
Cerevel Therapeutics, LLC

Recruiting

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Apathy in Dementia

United States, Canada
Cerevel Therapeutics, LLC

Recruiting

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary
Cerevel Therapeutics, LLC

Recruiting

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria
Cerevel Therapeutics, LLC

Completed

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

Schizophrenia | Blood Pressure

United States
Cerevel Therapeutics, LLC

Completed

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

Parkinson Disease

United States
Yale University
National Institute of Mental Health (NIMH); University of Pennsylvania; Columbia... and other collaborators

Recruiting

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

Early Course Schizophrenia Spectrum Disorder

United States
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Renal Impairment

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Renal Impairment

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Completed

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Schizophrenia

Belgium, United States
Cerevel Therapeutics, LLC

Completed

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

Schizophrenia

United States
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar

Georgia
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary, Puerto Rico
Takeda

Terminated

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Cardiovascular Disease | Type 2 Diabetes

United States, France, Poland, Ukraine, Germany, Hong Kong, Taiwan, Argentina, Israel, Mexico, Bulgaria, Malaysia, Romania, Canada, Korea, Republic of, New Zealand, Peru, Estonia, Philippines, Russian Federation, Czech Republic, H... and more
Molecular NeuroImaging
Life Molecular Imaging SA

Completed

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

Alzheimer's Disease (AD) | Progressive Supranuclear Palsy (PSP) | Frontal Temporal Dementia (FTD) | Cortical Basal Syndrome (CBS)

United States
Takeda

Terminated

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes (GRAND-307)

Type 2 Diabetes Mellitus

Taiwan, China, Korea, Republic of, New Zealand, Australia
Carmot Therapeutics, Inc.

Recruiting

A Study of CT-868 in Type 1 Diabetes Mellitus

Overweight | Type 1 Diabetes Mellitus | Obese

United States
Atara Biotherapeutics

Recruiting

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Allogeneic Hematopoietic Cell Transplant | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)

United States, Austria, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
Cerevel Therapeutics, LLC

Recruiting

A Multiple Ascending Dose Trial of Emraclidine in Elderly Participants

Healthy Participants

United States
Indonesia University
Dr Cipto Mangunkusumo General Hospital

Completed

Depth of Necrosis in Normal Cervical Epithelium After 85% Trichloroacetic Acid (TCA) Application

Cervix; Intraepithelial Neoplasia

Indonesia
Horizon Therapeutics Ireland DAC

Recruiting

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Netherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
Robert Mack, M.D.

Unknown

Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2

Keratoconus | Corneal Ectasia

United States
Bayer

Completed

Evaluation of the Stinging Potential in Human Eyes

Sunscreen Agents

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy

Epilepsy

United States, Germany
Cerevel Therapeutics, LLC

Recruiting

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

Healthy Participants

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
Cerevel Therapeutics, LLC

Completed

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

Healthy Participants

United States
NCIC Clinical Trials Group
Cascadian Therapeutics Inc.

Completed

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Glioblastoma

Canada
NCIC Clinical Trials Group
Oncothyreon Canada Inc.

Completed

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

Canada
Cascadian Therapeutics Inc.

Completed

Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers

Healthy Volunteer

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy

Partial Epilepsy

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Enrolling by invitation

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Korea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
Takeda

Completed

Open-label Study of TAK-875

Diabetes Mellitus

Japan
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

United States, Canada, Singapore, Taiwan
Takeda

Completed

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Breast Neoplasm | Ovarian Neoplasm | Pancreatic Neoplasm | Lung Neoplasm | Renal Neoplasm

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

Psoriasis
Cerevel Therapeutics, LLC

Terminated

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

Substance Use Disorders (SUD)

United States
Takeda

Recruiting

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Narcolepsy Type 1 | Narcolepsy Type 2

Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
AbbVie

Completed

A Phase 1 Study of ABT-869 in Subjects With Solid Tumors

Solid Tumor
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

Advanced Solid Tumors
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

Gastrointestinal Adenocarcinomas

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects

Schizophrenia

Search clinical trials for: CVL-865

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations